Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines recent findings on SCD1 dependence in lung adenocarcinoma with concurrent STK11/KEAP1 mutations, and the potential of SCD1 as a therapeutic target. The co-mutations increase the proliferative and invasive potential of lung adenocarcinoma cells, and up-regulate genes involved in evading ferroptosis, a form of non-apoptotic cell death, such as SCD1. Inhibiting SCD1 decreased tumor activity, which suggests SCD1 is a suitable therapeutic target for this subset of lung adenocarcinoma. This interview took place during the ESMO TAT 2021 conference.